NCT01303341View on ClinicalTrials.gov

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 18, 2011

Primary Completion Date

May 1, 2012

Study Completion Date

September 17, 2026

Conditions
Advanced Malignant Solid NeoplasmRecurrent MelanomaRefractory Malignant Solid NeoplasmStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Riluzole

Given PO

DRUG

Sorafenib Tosylate

Given PO

Trial Locations (1)

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH